Item 8.01. Other Events.
On September 19, 2020, the Company issued a press release titled "Trodelvy(TM)
Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic
Triple-Negative Breast Cancer". The full text of the press release is attached
to this current report on Form 8-K as Exhibit 99.1 and is incorporated by
reference herein.
On September 19, 2020, the Company issued a press release titled "Immunomedics
Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of
Trodelvy(TM) in Metastatic Urothelial Cancer". The full text of the press
release is attached to this current report on Form 8-K as Exhibit 99.2 and is
incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are being filed herewith:
Exhibit Exhibit
No.
99.1 Press Release of Immunomedics, Inc., dated September 19,
2020
99.2 Press Release of Immunomedics, Inc., dated September 19,
2020
104 The cover page from this Current Report on Form 8-K, formatted
in Inline XBRL
© Edgar Online, source Glimpses